|
The Professional
Opinions section brings you excerpts from books and articles,
interviews with professionals in the mental health field,
and notable quotes from the literature on psychiatry and parenting.
We welcome
your comments on the information in this section in the parent-to-parent
section of WhatMeds.com, or email us at info@whatmeds.com.
| Dr.
Kiki D. Chang, Stanford University School of Medicine |
| Dr.
Kiki D. Chang is Assistant Professor at the Stanford
University School of Medicine . He is Director of the
Pediatric Mood Disorders Clinic, Division of Child Psychiatry
and Child Development. Cathleen Schmonsees, R.N., met
with Dr. Chang at his Stanford office for this interview
for WhatMeds.com. |
| Question: |
You
are a child psychiatrist specializing in bipolar
disease. Drug therapy seems as important as "talk"
therapy. How do you determine dosage? |
| Answer: |
One
of the difficulties that a physician faces is
the time necessary to arrive at an optimum dose,
and the patience required to allow the medication
to work at therapeutic levels. So often, parents
arrive with a list of medications taken, having
tried them for short periods, stating that the
medication did not work. As a general rule,
an antidepressant may take from 4 to 6 weeks,
whereas Ritalin would show efficacy much more
rapidly. Blood testing for levels of depakote
permit very precise dosing information, and
help assure the child's safety as well. There
are also relatively objective ways to judge
the effect of the medication on behavior, including
scales which rate symptom severity. Some of
the rating scales which are used in my practice
are the Kiddie-Young Mania Rating Scale, and
the Child and Adolescent Mood State Scale by
Robert Kowatch, M.D. for Bipolar Disorder (CAMSS).
We also utilize the Childhood Depression Inventory
(CDI) for depression. These scales provide a
numerical system of evaluation to monitor the
effectiveness of the prescribed medication.
|
| Question: |
Do
you think there are too many kids getting medication
today? |
| Answer: |
This
is a very complex question. There may be a population
of children for which non-medication interventions
would be preferable, but these interventions
may not be readily available to the families,
whether due to limited financial resources or
because HMOs will not cover enough therapy sessions.
There are also, undoubtedly, large numbers of
children who are not receiving medication who
could be benefiting from it. I think the greater
problem is the shortage of child psychiatrists
in most areas. We need folks who are specifically
trained to treat children with appropriate psychotropic
medications. Thus, in certain geographical areas,
children are probably under or mis-diagnosed,
and perhaps not treated as properly as they
could be.
|
| Question: |
Is
there one diagnosis which you encounter most frequently?
|
| Answer: |
Yes,
I specialize in bipolar disorder, but with this
diagnosis there are often many other related
diagnoses which must be addressed: depression,
ADHD, cyclothymia, anxiety disorders, oppositional
defiant disorder, conduct disorder, etc.
|
| Question: |
How
do you arrive at a diagnosis? |
| Answer: |
We
have very specific features to look for, based
on the DSM IV. However, in my own practice,
family history becomes very important as a tool
in helping to make a more conclusive diagnosis.
I have been conducting a study of children who
have bipolar parents. We have recruited these
families in order to study them, and our first
step is to give a structured diagnostic interview
to establish any psychiatric diagnoses in the
children . We have been working with six to
eighteen year olds. For some subjects, we perform
brain imaging with magnetic resonance imaging
(MRI). We are particularly excited about our
studies using functional magnetic resonance
imaging (fMRI), which shows us which areas of
the brain the child is using when they perform
various tasks. Then we may compare these images
with "normal" healthy children. This
is very exciting research, and it should allow
us to understand better which areas of the brain
may be dysfunctional in bipolar disorder.
|
| Question: |
What
is your opinion of Depakote? |
| Answer: |
We
are finding it to be an excellent mood stabilizer
for bipolar children. We will be presenting
the results of a research study on the efficacy
of Depakote in children with bipolar parents
who have mood or behavioral problems in October,
2000. So far, we are encouraged by our results.
|
| Question: |
Do
you feel there is an increase in bipolar disorder? |
| Answer: |
It
appears that there has been a general increase
in the diagnosis of bipolar disorder in children,
and this might be due to in part to an increasing
public awareness that the disorder may appear
in children, or in part, perhaps, to an over-diagnosis
of the disorder in certain areas. However, there
is a theory of genetic anticipation, which may
hold true with bipolar disorder, and that theory
is that with each succeeding generation, the
mood problems may present themselves at an earlier
age. Since the brain chemistry of a six year
old is very different from that of an adult,
bipolar disorder may be difficult to diagnose
in small children.
|
| Question: |
What
about the side effects from Depakote, isn't it
used primarily for seizure disorders? |
| Answer: |
It
is used for seizure disorders, however we find
it to be effective in treating bipolar disorder.
Some of the most common side effects are sedation
and an increase in appetite, which often leads
to weight gain. That can be problematic, especially
for adolescents who are concerned about body
image.
|
| Question: |
Do
psychiatrists still use tricyclics and MAOIs? |
| Answer: |
I
can only speak for myself. I do not use MAOIs
due to the dietary restrictions. Tricyclics
are very rarely used.
|
| Question: |
It
has been said that psychiatry is just coming out
of the "dark ages." What do you envision
in the next 5 years? |
| Answer: |
I'd
agree that we are coming out of the dark ages
regarding psychopharmacology in children and adolescents.
Much of the research that's been done has been
on adults, and while some data can be applied
to children, it is essential to have "child"
studies. We are seeing a significant increase
in this area. The government is now encouraging
pharmaceutical manufacturers to obtain data on
treatment for children. They have done this by
granting extensions on patents. Typically, an
additional six months is added to the term of
helping the patent, generating additional profit
for the pharmaceutical manufacturer and helping
to defray the high cost of drug studies. |
|
Back
to top
|